Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-cash Items: 2011-2024

Historic Non-cash Items for Heron Therapeutics (HRTX) over the last 11 years, with Dec 2024 value amounting to $9.6 million.

  • Heron Therapeutics' Non-cash Items rose 181.02% to $385,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $385,000, marking a year-over-year increase of 181.02%. This contributed to the annual value of $9.6 million for FY2024, which is 15.81% down from last year.
  • Latest data reveals that Heron Therapeutics reported Non-cash Items of $9.6 million as of FY2024, which was down 15.81% from $11.4 million recorded in FY2023.
  • Heron Therapeutics' 5-year Non-cash Items high stood at $13.7 million for FY2022, and its period low was $9.6 million during FY2024.
  • For the 3-year period, Heron Therapeutics' Non-cash Items averaged around $11.5 million, with its median value being $11.4 million (2023).
  • In the last 5 years, Heron Therapeutics' Non-cash Items skyrocketed by 18,083.31% in 2020 and then dropped by 16.56% in 2023.
  • Heron Therapeutics' Non-cash Items (Yearly) stood at $10.2 million in 2020, then grew by 19.60% to $12.2 million in 2021, then increased by 11.48% to $13.7 million in 2022, then declined by 16.56% to $11.4 million in 2023, then decreased by 15.81% to $9.6 million in 2024.